Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
NEW YORK, Dec. 16, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated...
-
NEW YORK, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated...
-
Data from pilot trial of AT-007 in SORD deficiency expresses substantial and significant reduction in sorbitol Data from the ACTION-Galactosemia Kids study demonstrates statistically significant...
-
Substantial and significant reduction in sorbitol Company plans to initiate registrational trial by end of 2021 Company to host conference call and webcast today at 8:30 a.m. ET NEW YORK, Oct. 25,...
-
Substantial and statistically significant reduction in plasma galactitol of 40% with new weight-based dosing parameters Baseline galactitol levels clearly correlated with baseline clinical functional...
-
Substantial and statistically significant reduction in plasma galactitol Baseline analysis demonstrates clear relationship between plasma galactitol level and severity of disease in pediatric...
-
NDA submission for AT-007 in Galactosemia expected in Q3 2021; commercial preparations ongoing Ended Q2 2021 with a strong balance sheet with $125.6 million in cash and cash equivalents and...
-
NEW YORK, June 28, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated...
-
~1 in 5 people with diabetes or pre-diabetes have Diabetic Cardiomyopathy, a serious and progressive disease that limits the heart’s ability to function People with diabetes or pre-diabetes who have...
-
NEW YORK, June 21, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated...